Publications by authors named "Richard Jon Schmiesing"

Positive modulators at the benzodiazepine site of α2- and α3-containing GABA(A) receptors are believed to be anxiolytic. Through oocyte voltage clamp studies, we have discovered two series of compounds that are positive modulators at α2-/α3-containing GABA(A) receptors and that show no functional activity at α1-containing GABA(A) receptors. We report studies to improve this functional selectivity and ultimately deliver clinical candidates.

View Article and Find Full Text PDF

Positive modulators at benzodiazepine sites of α2- and α3-containing GABA(A) receptors are believed to be anxiolytic. Negative allosteric modulators of α5-containing GABA(A) receptors enhance cognition. By oocyte two-electrode voltage clamp and subsequent structure-activity relationship studies, we discovered cinnoline and quinoline derivatives that were both positive modulators at α2-/α3-containing GABA(A) receptors and negative modulators at α5-containing GABA(A) receptors.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Richard Jon Schmiesing"

  • - Richard Jon Schmiesing's research focuses on the development of functionally selective allosteric modulators of GABA(A) receptors, particularly targeting specific subtypes to enhance therapeutic effects while minimizing side effects.
  • - The findings highlight the identification of compounds that act as positive modulators at α2- and α3-containing GABA(A) receptors, potentially offering anxiolytic effects, while showing no activity at the α1 subtype.
  • - His work also includes the discovery of dual functional allosteric modulators that serve as both positive modulators at α2-/α3-containing GABA(A) receptors and negative modulators at α5 subtypes, potentially improving cognitive outcomes.